- Home
- GLTO vs PPCB Comparison
GLTO vs PPCB Comparison
Compare GLTO & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- PPCB
- Stock Information
- Founded
- GLTO 2011
- PPCB 2007
- Country
- GLTO Denmark
- PPCB Australia
- Employees
- GLTO N/A
- PPCB N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- PPCB
- Sector
- GLTO Health Care
- PPCB
- Exchange
- GLTO Nasdaq
- PPCB Nasdaq
- Market Cap
- GLTO 23.7M
- PPCB 20.4M
- IPO Year
- GLTO 2020
- PPCB N/A
- Fundamental
- Price
- GLTO $16.82
- PPCB $0.79
- Analyst Decision
- GLTO
- PPCB
- Analyst Count
- GLTO 0
- PPCB 0
- Target Price
- GLTO N/A
- PPCB N/A
- AVG Volume (30 Days)
- GLTO 3.4M
- PPCB 225.5K
- Earning Date
- GLTO 11-06-2025
- PPCB 11-17-2025
- Dividend Yield
- GLTO N/A
- PPCB N/A
- EPS Growth
- GLTO N/A
- PPCB N/A
- EPS
- GLTO N/A
- PPCB N/A
- Revenue
- GLTO N/A
- PPCB N/A
- Revenue This Year
- GLTO N/A
- PPCB N/A
- Revenue Next Year
- GLTO N/A
- PPCB N/A
- P/E Ratio
- GLTO N/A
- PPCB N/A
- Revenue Growth
- GLTO N/A
- PPCB N/A
- 52 Week Low
- GLTO $2.01
- PPCB $0.73
- 52 Week High
- GLTO $33.60
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- GLTO 55.60
- PPCB N/A
- Support Level
- GLTO $15.76
- PPCB N/A
- Resistance Level
- GLTO $29.03
- PPCB N/A
- Average True Range (ATR)
- GLTO 4.83
- PPCB 0.00
- MACD
- GLTO -0.52
- PPCB 0.00
- Stochastic Oscillator
- GLTO 43.02
- PPCB 0.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.